Not provided
Not provided
Not provided
Not provided
recruitment difficulty
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This Phase III study will compare the efficacy and tolerability of a Fixed Dose Combination of Etodolac + Cyclobenzaprine versus the isolated drugs in postoperative pain control after impacted third molar extraction.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | Experimental | 1 active treatment (Fixed Dose Combination) + 2 placebos |
|
| Group 2 | Active Comparator | 1 active treatment (Cyclobenzaprine) + 2 placebos |
|
| Group 3 | Active Comparator | 1 active treatment (Etodolac) + 2 placebos |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fixed Dose Combination | Drug | Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Superiority of the Fixed Dose Combination versus Isolated active substances | The Primary outcome will be accessed by the individual response rate in relation to the pain intensity calculated by the Visual Analogic Scale (VAS) scale performed after 4 hours of administration of the first dose of medicines | 4 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Individual response rate | Individual response rate in relation to the evaluation of pain intensity calculated through the Visual Analogic Scale (VAS) measure in times 6h, 12h, 24h, 48h and 72h | 6h, 12h, 24h, 48h and 72h |
| Edema |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Azidus Brasil Pesquisa CientÃfica e Desenvolvimento Ltda. | Valinhos | São Paulo | 13271-130 | Brazil |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Etodolac |
| Drug |
Individual drug |
|
|
| Cyclobenzaprine | Drug | Individual drug |
|
|
Absence of edema after 4 hours of drug administration and at the end of treatment
| 4 hours |
| Mandibula constriction | Absence of mandibular constriction after 4 hours of drug administration and at the end of treatment | 4 hours |
| Use of rescue medication | Proportion of participants requiring the use of rescue medication over the 3 days of treatment in each treatment group | 3 days |
| ID | Term |
|---|---|
| D059787 | Acute Pain |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D017308 | Etodolac |
| C004704 | cyclobenzaprine |
| ID | Term |
|---|---|
| D007210 | Indoleacetic Acids |
| D000147 | Acids, Heterocyclic |
| D006571 | Heterocyclic Compounds |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided